Immune thrombocytopenia (ITP): focus on raising platelet counts

Platelet counts < 50 x 109/L introduce increased risk for bleeding events1,2

Symptoms and risks of ITP1,2

Symptoms and risks Symptoms and risks

Treatment options

2011 American Society of Hematology (ASH) guidelines and International Consensus Report (ICR) recommendations for first-line ITP treatment options include corticosteroids as well as anti-D and intravenous immunoglobulins (IVIG).3,4

Administer Nplate® at the first sign of relapse following first-line therapy5

Both the 2011 ASH and ICR recommendations include Nplate® as one of the second-line treatment options for ITP.3,4

Important Safety Information

Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

  • In Nplate® clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
  • Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP.

Thrombotic/Thromboembolic Complications

  • Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate® use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate®.
  • To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of ≥ 50 x 109/L.

Loss of Response to Nplate®

Laboratory Monitoring

Adverse Reactions

Indication

Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than chronic ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

Please see full Prescribing Information and Medication Guide.